Table 3. Fold increase in anti-peptide IgG titer in subjects enrolled in 5 schedules.
| Group | W-4 | W-7 | W-10 | W-13 | W-22 | W-46 | W-70 |
|---|---|---|---|---|---|---|---|
| A | 4 | 32 | 32 | 16 | 16 | 16 | 8 |
| A | 1 | 4 | 4 | 2 | 2 | 2 | 2 |
| A | NA | NA | 64 | 32 | 16 | 16 | 32 |
| A | 1 | 1 | 1 | N/A | N/A | N/A | N/A |
| A | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| W-7 | W-10 | W-13 | W-16 | W-22 | W-46 | W-70 | |
| B | 1 | 1 | 1 | 1 | 1 | 8 | 8 |
| B | 1 | 1 | 1 | 1 | 4 | 8 | 8 |
| B | 4 | 16 | 16 | 64 | 32 | 16 | N/A |
| B | 1 | 1 | 2 | 2 | 2 | 1 | 2 |
| B | 16 | 32 | 32 | 32 | 8 | 4 | 4 |
| W-7 | W-10 | W-13 | W-16 | W-25 | W-49 | W-73 | |
| C | 8 | 32 | 32 | 4 | 4 | 2 | 2 |
| C | 4 | 4 | 4 | 32 | 32 | 32 | N/A |
| C | 8 | 16 | 32 | 64 | 64 | 64 | N/A |
| C | 1 | 1 | 1 | 1 | 1 | 8 | 4 |
| C | 64 | 256 | 256 | 256 | 64 | 16 | 32 |
| W-5 | W-8 | W-11 | W-14 | W-23 | W-47 | W-71 | |
| D | 1 | 4 | 4 | 8 | N/A | 8 | N/A |
| D | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| D | 8 | 16 | 16 | 8 | 8 | 16 | N/A |
| D | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| D | 2 | 1 | 1 | 2 | 1 | 1 | 16 |
| W-6 | W-9 | W-12 | W-15 | W-24 | W-48 | W-72 | |
| E | 4 | 8 | 32 | N/A | N/A | NA | N/A |
| E | 2 | 4 | 4 | 8 | 8 | 16 | 8 |
| E | 2 | 8 | 4 | N/A | N/A | N/A | N/A |
| E | 4 | 4 | 4 | N/A | N/A | N/A | N/A |
| E | 4 | 2 | 2 | N/A | N/A | N/A | N/A |
Antibody titer was determined in pre-immune samples and at various times (weeks, W) after immunization. The fold increase in antibody titer (relative to pre-immune levels) is reported.